Hollywood Private Hospital starts HyCASA training

Wednesday, 03 August, 2022

Hollywood Private Hospital starts HyCASA training

Hollywood Private Hospital is set to become a training and education hub in Australasia for the specialist heart procedure Hybrid Catheter Ablation and Surgical Ablation (HyCASA).

Cardiothoracic Surgeon Pragnesh Joshi and Cardiac Electrophysiologist Rukshen Weerasooriya are said to be the only practitioners performing HyCASA in the Southern Hemisphere and are expected to train 12 teams in the next 18 months.

The first team to train were clinicians from Peninsula Private Hospital and Monash Medical Centre in Melbourne. The team, including a cardiothoracic surgeon, two electrophysiologists, an anaesthetist and a scrub nurse, visited Hollywood on 28 and 29 July. They watched the two surgical procedures in theatre and then discussed HyCASA with Weerasooriya.

HyCASA is a keyhole minimally invasive surgery performed on a beating heart. It is for patients with long-standing persistent atrial fibrillation (AF or Afib). Atrial fibrillation is an abnormal heart rhythm caused by erratic electrical signals in the heart, and affects about 2% of the Australian population, said Ramsay Health in a statement.

The aim of HyCASA is to interrupt the atrial fibrillation circuits and return the heart back to a normal rhythm. It combines endocardial radiofrequency ablation (which treats the inside of the heart) with epicardial ablation (which treats the outside of the heart).

The experiences and outcomes from the Hollywood team will be delivered via podium presentations at Australian and international clinical conferences.

Weerasooriya said a comprehensive HyCASA training program is important to provide AF patients with increased access to the specialist procedure across Australia, New Zealand and the Asia–Pacific.

“All participants need to be fully briefed on a new procedure for optimal outcomes for the patient,” Weerasooriya said.

Atrial fibrillation increases the risk of stroke, heart failure, chronic fatigue, decreased activity levels and a diminished quality of life.

In 2017–18, atrial fibrillation is said to have accounted for more than 72,000 hospitalisations in Australia and 9% of deaths were associated with the condition in 2018, the statement said.

Most patients considered for HyCASA have persistent AF (AF that lasts continuously for more than seven days) or previous procedures have not been effective. It is estimated almost half of AF patients have long-standing and persistent AF.

Hearts4Heart CEO Tanya Hall said HyCASA provides an important alternative for patients when other therapies have failed.

“These are the patients with the most debilitating levels of atrial fibrillation where no other therapy has proven successful,” Hall said.

“We would like to see more surgeons being trained in HyCASA so that it is accessible for all patients, in all states across Australia.”

Hollywood Private Hospital CEO Andrew Tome said it is the mission of Hollywood to offer new and innovative therapies for patients who have had limited options in the past.

“We are proud to support specialists in their clinical research and technique development,” Tome said.

Related News

Tool helps cancer survivors manage post-treatment uncertainty

UNSW researchers are using e-health to investigate ways to help cancer survivors access treatment...

Need to cut through alcohol and breastfeeding misinformation

Two-thirds of Australian women who breastfeed feel they do not fully understood the risks of...

Study explores techniques for reducing needle anxiety

A University of South Australia study has found two new nurse-led techniques that help reduce...

  • All content Copyright © 2022 Westwick-Farrow Pty Ltd